However, these medications, classified as GLP-1 receptor agonists (for Semaglutide) and dual GLP-1/GIP receptor agonists (for Tirzepatide), are now being explored for a variety of other potential health benefits beyond their established uses including: improving cardiovascular health, exerting neuroprotective effects, exhibiting anti-inflammatory properties, ad potentially benefitting conditions such as polycystic ovary syndrome (PCOS) and chronic kidney disease
Combining phentermine and tirzepatide may amplify certain adverse effects and introduce unique safety concerns that require careful clinical monitoring
According to the American Diabetes Association's Standards of Care, GLP-1 RAs with proven cardiovascular benefit, such as semaglutide, may be considered as first-line therapy in patients with type 2 diabetes who have established atherosclerotic cardiovascular disease or high cardiovascular risk, independent of metformin use
About Us Sinoway was established in 1987, and is specialized in research, development, custom manufacturing and trading of pharmaceutical APIs, Intermediates, health & food supplements, cosmetic raw materials, herbal extracts, FDFs and custom service all over the world
Moreover, our focus was solely on the impact of different routes of administration on adverse events (AEs), without excluding other confounding factors such as adherence to prescribed administration schedules or dosages, which could potentially influence (AEs)
